Moderna (NASDAQ:MRNA) initiated with Buy rating and $25 (64% upside) price target at Goldman Sachs. Initiated with Overweight rating and $22 price target at JPMorgan. Initiated with Overweight rating and $24 price target at Piper Jaffray. Initiated with Overweight rating and $29 price target at Morgan Stanley. Initiated with Outperform rating and $27 price target at Oppenheimer.
Bausch Health Companies (NYSE:BHC) upgraded to Overweight with a $27 (46% upside) price target at Piper Jaffray.
Stryker (NYSE:SYK) upgraded to Outperform at Evercore ISI.
Hologic (NASDAQ:HOLX) downgraded to Underweight at Morgan Stanley. Shares down 3% premarket.
Ultragenyx Pharmaceutical (NASDAQ:RARE) downgraded to Market Perform at Raymond James. Shares down 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.